ICON plc (ICLR) stock had a bullish inflow of $31.01 million worth of trades on uptick and an outflow of $27.8 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.12. The net money flow into the stock was $3.21 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $3.44 million. An inflow of $15.28 million block trade was recorded on downticks. $18.72 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 1.23 in favor of the bulls. However, ICON plc (ICLR) stock traded down $0.13 , and reached $70.97, a drop of -0.18% over the previous day. On a weekly basis, the stock is 0.47%, over the previous weeks close.
ICON plc (ICLR) : The highest short term price target forecast on ICON plc (ICLR) is $87 and the lowest target price is $59. A total of 7 equity analysts are currently covering the company. The average price of all the analysts is $76.71 with a standard deviation of $9.81. The stock has recorded a 20-day Moving Average of 5.32% and the 50-Day Moving Average is 6.13%.
ICON plc (NASDAQ:ICLR): The stock opened at $71.49 on Thursday but the bulls could not build on the opening and the stock topped out at $71.50 for the day. The stock traded down to $70.65 during the day, due to lack of any buying support eventually closed down at $70.97 with a loss of -0.18% for the day. The stock had closed at $71.10 on the previous day. The total traded volume was 1,628,845 shares.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.